Cryotherapy With or Without Short-term Adjuvant Androgen-Deprivation Therapy in Prostate Cancer

Inclusion Criteria: 1. Age\>20 years 2. Histopathology proven prostate adenocarcinoma 3. Non-metastatic localized disease 4. Prostate cancer is deemed high-risk for recurrence(PSA\>20 ng/ml, Gleason score\>=8, or clinical staging\>=T2c) 5. Subjects have undergone prostate cryoablation as the definitive treatment prior to enrolling the study 6. Subjects who have not been treated with any definitive treatments for prostate cancer, including radical prostatectomy or definitive radiotherapy. However, those who have undergone focal prostate cryoablation and have cancer recurrence are still eligible. 7. Subjects may or may not have received neoadjuvant androgen-deprivation therapy (ADT) in the forms of either castration (medical) and/or antiandrogens. Surgical castration (orchiectomy) is not allowed. 8. Subjects are willing to sign the informed consent and agree to comply with the study procedures Exclusion Criteria: 1. Those who have been treated with \> 8 weeks (collectively if not continuously) of neoadjuvant ADT prior to screening. 2. Subjects who have other cancer that is deemed not cured or are known less than 5 years except for basal cell carcinoma of the skin 3. Other conditions the investigators think may affect subject compliance or safety